1 / 24

NALOXONE Intervention to Reduce Drug-Related Deaths Post-Prison Release

Study on the effectiveness of NALOXONE - a heroin antidote - to prevent overdose deaths among recently released prisoners, aiming to reduce Drug-Related Deaths (DRDs). Research conducted in HMP Edinburgh involving male ex-prisoners, focusing on the importance of timely intervention and education to decrease mortality rates.

neldam
Download Presentation

NALOXONE Intervention to Reduce Drug-Related Deaths Post-Prison Release

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug-Related Deaths (DRDs) soon after release: IEffectiveness on Trial: IINaloxone (heroin antidote) on release to reduce overdose deaths (sheila.bird@mrc-bsu.cam.ac.uk)

  2. HMP Edinburgh

  3. John Pearce, former governor of Edinburgh Prison, 1990 Dr. A. Graham Bird,clinical immunologist.

  4. 1991 WASH Willing[ethical] Anonymous [no deductive disclosure] Saliva & linked self-Q [high volunteer rate] HIV surveillance Linked to self-Qon risks [frank answers]

  5. 1. Seaman,Brettle &Gore: BMJ (1998) Overdose deaths in 2 weeks after HIV injectors’ releases fromHMP Edinburgh [1983-94] 8 times higherthan for comparable other fortnights at liberty (p < 0.01) 7 drug-related deaths, 6 from overdose.

  6. 2. Male index releases from Scottish prisons in July to Dec. 1996-99 [Bird & Hutchinson: Addiction 2003] Eligibility set by [B+H] Applied by Scottish Prison Service [SPS] male born in 1960+ & aged 15-35 years on release served 14+ days in prison 1st release in July-December calendar years: 1996 to 1999

  7. Design assumptions • ~ 20,000 eligible releases 2. At least 40% adult & 20% young offender male index releases = injectors (IDUs) 3. Drugs-Related Deaths (DRDs): mainly IDUs • In 1990s: one DRD per 3000 recently released IDU-days (not 1 per 1000, as Seaman) 5. Relative Risk: 1st fortnight DRDs = 4

  8. Drugs-related deaths in fortnight after prison: 19 486 male ex-prisoners, aged 15-35 years, released after 14+days’ incarceration

  9. 1 in 200 adult injectors dead within 2 weeks after prison Judges aware?

  10. Internationally, 6 major studies

  11. Why prisoners + outside implications? Need + Research Efficiency • concentration of adult heroin injectors (~ 40%) ii) at very high risk iii) well-defined period soon after release iv) Third to half injectors in prison in past year v) proof-of-principle for other settings 1 in 8 Scottish DRDs occurs in 4 weeks after release!

  12. Prison-based interventions • Information leaflet:how to avoid overdose risk after release b) Naloxone on release:heroin antidote

  13. UK’s Advisory Council on the Misuse of Drugs: already on the case in 2000 . . . 2005 Naloxone was added to UK’s exempt list of Prescription Only Medicines for administration by anyone in an emergency to save life

  14. N-ALIVE: randomise 56,000 eligible prisoners in 50 UK prisons in 5 years “Good luck, Prof Bird . . . “ Three musketeers (2008): John Strang, Max Parmar & Sheila Bird

  15. Design assumptions: N-ALIVE Eligibility: 18-44 years, history of heroin injection, 7+ days’ incarceration. 1. At 80% of overdoses, some-one else is present 2. 75% chance ex-prisoner carries Naloxone in 1st 4 weeks post-release; 50% chance in next 8 weeks 3. 50% chance that Naloxone is administered by present other. • Effectiveness in 1st 4 weeks = 30% Effectiveness in weeks 5 to 12 = 20% • 21st C: One overdose death in 1st 4 weeks per 200 ever-IDUs randomised to control group. 5. Contamination . . .

  16. Prison-based, with-consent* RCT for 56,000 pre-release adult IDUs

  17. If CE threshold is £20K($40K) per life year gained, & Naloxoneprevents 42drug deaths in 1st+2nd fortnight per 28,000 IDU releases  Per injector-inmate, UK’s NHS can afford to pay: {42 * £20K}/28,000 = £30 for pre-release Naloxone UK-affordable cost of Naloxone

  18. N-ALIVE designed to fit with UK prison routines . . .Induction: drug awareness +N-ALIVE DVD1-1 consent: each randomized prisoner has an assignedN-ALIVE pack.Assigned N-ALIVE packs held inPharmacy or Prisoner’s valuables.Prisoner escort  release from court . . .Date of release is critical.*N-ALIVE DVD copy for prisoner’s family ** Re-randomization of recidivists . . . ?

  19. N-ALIVE cleaves to prison routines Prisoner-induction includes drugs awareness session: N-ALIVE DVD added. (educates peers/family re N-ALIVE & Naloxone) N-ALIVE addiction workers: informed consent, randomisation, liaison with pharmacy & Clinical Trials Unit re release dates. (half-time is research activity) N-ALIVE pack handled by pharmacy & escort staff as a medicine that accompanies prisoner to court, on transfers. (issued only on release)

  20. Informed consent by prisoners • Treatments = Naloxoneor control pack at release [information leaflet & prepaid reply card] • Confidential database linkage to deaths register [and NFO A&E admissions in N-ALIVE PILOT RCT] • Random assignment ~ blinded until release • Follow-up of recidivists via brief self-Q (unique #) • Single phone contact in 1st or 2nd fortnight after release (for HALF only of randomised participants & in PILOT RCT only . . . Because phone-contact contaminates N-ALIVE intervention)

  21. N-ALIVE Recidivist self-Q RCT flag against prisoner numberso thaton re-incarceration [applies to 60% of IDUs] IDU attends prison health to answer no-names, selotape-seal, self-Q re overdose(s) witnessed [fatal/non], overdose(s) experienced [alone/accompanied] & naloxone [use/disposal/acquisition/where kept] & heroin use.

  22. Pilot N-ALIVE . . . & kicking via Medical Research Council’s Clinical Trials Unit: welcomes international collaborations Scottish Prison Service (Karen Norrie, Andrew Fraser; Ruth Parker, Stephen Heller-Murphy; governors, security & HC) Health Department/Prison Service in E&W (Dave Marteau, Martin Lee) Prisoners in both services

More Related